View as Webpage


Volume 68 | January 31, 2023

A program of NIH’s National Center for Advancing Translational Sciences

Sites with Signed

DUAs

370

Sites Sharing Data with N3C



234

COVID-19

Positive

Patients

8,661,052

Rows

of Patient

Data

30.8 billion

Approved

N3C Research

Projects

527

As we reflect on 2023, it is with immense enthusiasm that N3C presents the '2023 Year in Review.' The past year has been a testament to collaborative team science and realizing accessible real-world data, and the community has made terrific progress in planning for the future. To view a snapshot of N3C’s remarkable achievements, click the button below.

2023 N3C Year In Review

What the Research Community is Saying about N3C

Joey P. Johnson, MD, FAAOS

Associate Professor

Director of Clinical Research

Department of Orthopedic Surgery

University of Alabama at Birmingham


The N3C collective allowed myself and my collaborators to gain a better understanding of how COVID-19 impacts the outcomes of orthopedic trauma patients on a national scale. The N3C allowed us the unique ability to leverage large scale data to determine how COVID changed the outcomes of inpatient fracture care in “Association between COVID-19 and Mortality in Hip Fracture Surgery in the National COVID Cohort Collaborative (N3C)” and “Outcomes of SARS-CoV-2 Infection Among Patients with Orthopaedic Fracture Surgery in the National COVID Cohort Collaborative (N3C)”, both of which were published in internationally recognized journals.

To help our community with a positive and productive workload, N3C schedules several “No Meeting Weeks” throughout the year.


N3C support will continue with regular operations during these dates. Most meetings will be canceled. Impromptu meetings can still occur to push through action items as needed during no meeting week. Workgroups and Domain Teams should check with their Leads to determine meeting schedules for that week. 

Upcoming N3Community Forums


*UPDATE*

Effective February 1, the N3Community Forum will move to once a month. Forums will take place on the 2nd Monday of each month at 2 pm PT / 5 pm ET.



Register for the Forum

12

February

AI Functionalities in the Enclave


Maya Choudhury, Palantir

Kate Bradwell, Palantir

Saad Ljazouli, Palantir

11

March

TBD

Missed an N3Community Forum or want to revisit a past Forum? You can find all the videos on our YouTube page.


Share your thoughts: Looking for ways to bring relevant and exciting presentations to the Forum. Let us know if there are topics, presentations, or speakers you would like to see: bit.ly/N3CForumFeedback

N3Community Forum Schedule

N3C In the News

Influence of Prior SARS-CoV-2 Infection on COVID-19 Severity: Evidence from the National COVID Cohort Collaborative

As SARS-CoV-2 has transitioned from a pandemic to endemic disease, the majority of new infections have been among previously infected individuals. To manage the risks and benefits of ongoing COVID-19 policies, it is important to understand whether prior infection modifies the severity of subsequent infections.

Datavant Joins NSF and Partners in Launch of the National AI Research Resource (NAIRR) Pilot Providing Privacy-Preservation Technologies to Safeguard AI-Enabled Data

In collaboration with 11 federal agencies, alongside private sector, nonprofit, and philanthropic organizations, the NAIRR pilot is set to offer U.S.-based researchers and educators access to cutting-edge computing, datasets, models, software, training, and user support. 

Effect of Paxlovid Treatment on Long COVID Onset: An EHR-Based Target Trial Emulation from N3C

Preventing and treating post-acute sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID, has become a public health priority. In this study, we examined whether treatment with Paxlovid in the acute phase of COVID-19 helps prevent the onset of PASC.

N3C Data Help Validate Two Clinical Tools to Predict COVID-19 Mortality Risk

For people hospitalized with COVID-19, two new risk-prediction tools, tested in part using the NCATS National COVID Cohort Collaborative (N3C), could help clinicians make faster, better treatment decisions.

Privacy‐preserving record linkage across disparate institutions and datasets to enable a learning health system: The national COVID cohort collaborative ( N3C ) experience

Introduction Research driven by real‐world clinical data is increasingly vital to enabling learning health systems, but integrating such data from across disparate health systems is challenging.

The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia

Although vaccines have proved effective to prevent severe COVID-19, their effect on preventing long-term symptoms is not yet fully understood.

Palantir Partners with University of Colorado Anschutz Medical Campus to Establish the All of Us Research Program’s Center for Linkage and Acquisition of Data (CLAD)

Palantir Technologies Inc. (NYSE: PLTR) today announced its partnership with the University of Colorado Anschutz Medical Campus to establish the Center for Linkage and Acquisition of Data (CLAD) as part of the National Institutes of Health’s (NIH) All of Us Research Program.

Privacy-preserving record linkage across disparate institutions and datasets to enable a learning health system: The national COVID cohort collaborative (N3C) experience

Research driven by real-world clinical data is increasingly vital to enabling learning health systems, but integrating such data from across disparate health systems is challenging. As part of the NCATS National COVID Cohort Collaborative (N3C), the N3C Data Enclave was established as a centralized repository of deidentified and harmonized COVID-19 patient data from institutions across the US. 

Doctors Aren’t Prescribing Paxlovid Often Enough. Here’s Why

Covid-19 infections and deaths have been steadily increasing in recent weeks, now reaching 1,500 deaths per week. There are antiviral drugs that still protect against severe infection and death, yet practitioners prescribe them infrequently. Why?

Drug-drug interaction between dexamethasone and direct-acting oral anticoagulants: A nested case-control study in the National COVID Cohort Collaborative (N3C)

Objective The goal of this work is to evaluate if there is an increase in the risk of thromboembolic events (TEEs) due to concomitant exposure to dexamethasone and apixaban or rivaroxaban.

Severe covid-19 infections linked to increased risk of schizophrenia

People with severe covid-19 infections are more than 4 times as likely to later be diagnosed with schizophrenia than people who have not been infected, though the risk of developing the condition is relatively low. 

More N3C In the News

Planning to Publish or Present Research Results? Here's how to find the policies.


Take 1 Minute!


  1. Navigate to covid.cd2h.org
  2. Hover over "Resources"
  3. Click on "Policies, Agreements, Forms"


Check out recent N3C Publications!


Remember, if you have a potential publication that references N3C, you must submit it to the N3C Publication Committee for review. Learn more about the publication review process here: https://covid.cd2h.org/publication-review

Browse Recent N3C Publications

Please report any questions, gaps, or errors to [email protected]

Gain Access to N3C Google Drive

Click Here

Off-board from N3C

Click Here

Report a Concern

Click Here

Have something you'd like featured in the N3Connect Bulletin?

Submit it to [email protected] for consideration.

The National COVID Cohort Collaborative (N3C) is a complementary and synergistic partnership among the Clinical and Translational Science Awards (CTSA) Program hubs, the National Center for Data to Health (CD2H), distributed clinical data networks (PCORnet, OHDSI, ACT, TriNetX), and other partner organizations, with overall stewardship by NIH’s National Center for Advancing Translational Sciences (NCATS). The N3C aims to improve the efficiency and accessibility of analyses using a very large row-level (patient-level) COVID-19 clinical dataset, demonstrate a novel approach for collaborative pandemic data sharing, and speed understanding of and treatments for COVID-19.

Visit the N3C Website
CD2H is supported by the National Center for Advancing Translational Sciences (NCATS) 
at the National Institutes of Health
(Grant U24TR002306).


Questions or Requests? Visit the Support Desk
Twitter  Youtube  Linkedin